NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Elanco Animal Health Incorporated (NYSE: ELAN) between November 7, 2023 and June 26, 2024, both dates inclusive (the “Class Period”), of the important December 6, 2024 lead plaintiff deadline. SO WHAT: If you purchased Elanco securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee a ...

NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN). Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/elanco-animal-health-incorporated-loss-submission-form/?id=114500& ...

SAN FRANCISCO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Animal health company Elanco (ELAN) and its most senior executives are the targets of a securities class action suit, alleging that they downplayed potential safety concerns related to Elanco’s new oral Janus kinase inhibitor, Zenrelia, while overstating its prospects for a rapid U.S. market entry. Hagens Berman urges Elanco Animal Health Incorporated (NYSE: ELAN) investors who suffered substantial losses to submit your losses now. Class Period: Nov. 7, 2023 ...

Core Viewpoint - A lawsuit has been filed against Elanco Animal Health Incorporated and certain senior executives for potential violations of federal securities laws, particularly concerning the FDA approval of key drug treatments [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court of Maryland, captioned Barpar v. Elanco Animal Health Incorporated, et al., No. 24-cv-02912 [2]. - Investors have until December 6, 2024, to request to be appointed to lead the case [2]. Group 2: Product Development and FDA Review - Elanco is developing two significant treatments: Zenrelia for dermatitis in dogs and Credelio Quattro, an oral parasiticide for fleas, ticks, and internal parasites [3]. - The company previously stated that the FDA had all necessary data for review and expected approvals by the end of June 2024 [4]. Group 3: Stock Price Impact - Following the announcement that the FDA would not approve the drugs as expected, Elanco's stock price fell over 21%, from $17.97 per share on June 26, 2024, to $14.27 per share on June 27, 2024 [5]. - The lawsuit investigates whether Elanco and its executives made materially false or misleading statements regarding the FDA's approval process [5]. Group 4: Legal Representation - Investors in Elanco may have legal options and are encouraged to submit their information to the law firm handling the case, with representation on a contingency fee basis [6]. - The firm has a strong track record in securities class actions and has recovered significant amounts for other clients [7].

Core Viewpoint - A lawsuit has been filed against Elanco Animal Health on behalf of investors who purchased its securities between November 7, 2023, and June 26, 2024, due to significant stock price decline following FDA approval updates [1][6]. Company Overview - Elanco Animal Health develops products for pets and farm animals, including Zenrelia, an oral Janus kinase inhibitor for canine dermatology, and Credelio Quattro, a parasiticide for dogs [3]. FDA Approval Timeline - In November 2023, Elanco set a timeline for U.S. FDA approval of Zenrelia and Credelio Quattro in the first half of 2024 [4]. - By May 2024, Elanco updated its timeline, expecting Zenrelia's approval and commercial launch in Q3 2024, and Credelio Quattro's approval in Q3 2024 with a launch in Q4 2024 [4]. - On June 27, 2024, Elanco indicated that Zenrelia would likely include a boxed safety warning, which could slow product adoption by approximately 25%, and revised its approval expectations to Q3 2024 for Zenrelia and Q4 2024 for Credelio Quattro [5]. Stock Price Impact - Following the FDA approval news, Elanco's stock price fell by $3.69 per share, or 20%, closing at $14.28 per share on June 27, 2024 [6].

Core Viewpoint - A lawsuit has been filed against Elanco Animal Health Incorporated and certain senior executives for potential violations of federal securities laws, particularly concerning the FDA approval of key drug treatments [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court of Maryland, titled Barpar v. Elanco Animal Health Incorporated, et al., No. 24-cv-02912 [2]. - Investors have until December 6, 2024, to request to lead the case [2]. Group 2: Product Development and FDA Review - Elanco is developing two significant treatments: Zenrelia for dermatitis in dogs and Credelio Quattro, an oral parasiticide for fleas, ticks, and internal parasites [3]. - The company previously stated that the FDA had all necessary data for review and expected approval by the end of June 2024 [4]. Group 3: Stock Price Impact - Following the announcement that the FDA would not approve the drugs as expected, Elanco's stock price fell over 21%, from $17.97 on June 26, 2024, to $14.27 on June 27, 2024 [5]. - The lawsuit investigates whether Elanco and its executives made materially false or misleading statements regarding the FDA's approval process [5]. Group 4: Legal Representation - Investors in Elanco may have legal options and are encouraged to submit their information to the law firm handling the case, which operates on a contingency fee basis [6]. - The firm has a strong track record in securities class actions, having recovered significant amounts from other companies [7].

NEW YORK, Dec. 01, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Elanco Animal Health Incorporated (NYSE: ELAN) between November 7, 2023 and June 26, 2024, both dates inclusive (the “Class Period”), of the important December 6, 2024 lead plaintiff deadline. SO WHAT: If you purchased Elanco securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee a ...

Core Viewpoint - A federal lawsuit has been filed against Elanco Animal Health Inc. and certain executives for allegedly making false and misleading statements regarding the safety and market prospects of Zenrelia, an oral Janus kinase inhibitor, during the class period from November 7, 2023, to June 26, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Elanco downplayed potential safety risks associated with Zenrelia while overstating its chances for a quick U.S. market launch [2]. - The controversy intensified on June 26, 2024, when Elanco announced that Zenrelia's label would include a boxed warning due to safety issues identified in trials with unvaccinated dogs, which is expected to significantly impede product adoption [3]. Group 2: Market Impact - Following the announcement of the boxed warning, Elanco's stock fell by over 20% [4]. - During the Q2 earnings call on August 4, 2024, CEO Jeffrey N. Simmons acknowledged that the warning would "slow the initial product adoption curve" and projected a 25% reduction in treatment days due to limitations related to vaccine usage [4]. Group 3: Investigation and Legal Actions - Law firm Hagens Berman is investigating the allegations to determine the accuracy and truthfulness of Elanco's representations regarding Zenrelia's safety [5]. - The firm is encouraging investors who have suffered substantial losses to come forward and submit their claims [6].

NEW YORK, Nov. 30, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...

NEW YORK, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elanco Animal Health Incorporated (NYSE:ELAN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Investors have until December 6, 2024 to ask ...